Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 3/20 | 0.61 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | STK16 | O75716 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.61 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.61 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.61 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050441 | 0.86 | EGFR (0.58) | GAKEPHB6RIPK2STK16ABL1 | |
| SCHEMBL27159593 | 0.86 | EGFR (0.58) | GAKEPHB6RIPK2STK16ABL1 | |
| SCHEMBL29892755 | 0.85 | GAK (0.61) | GAKEPHB6RIPK2STK16ABL1 | |
| SCHEMBL3304514 | 0.85 | GAK (0.61) | GAKEPHB6RIPK2STK16ABL1 | |
| SCHEMBL2621790 | 0.84 | PDGFRB (0.50) | GAKEPHB6RIPK2STK16ABL1 | |
| SCHEMBL360467 | 0.84 | GAK (0.47) | GAKEPHB6RIPK2STK16ABL1 | |
| SCHEMBL2621791 | 0.83 | GAK (0.46) | GAKEPHB6RIPK2STK16ABL1 | |
| SCHEMBL2621817 | 0.80 | AAK1 (0.44) | GAKEPHB6RIPK2STK16ABL1 | |
| SCHEMBL12390292 | 0.80 | PDGFRB (0.54) | GAKEPHB6RIPK2STK16ABL1 | |
| SCHEMBL30051292 | 0.80 | EGFR (0.52) | GAKEPHB6RIPK2STK16ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117247349-A | Quinoline oxynitride C 2 Process for the dithiocarbamation of H | 湖南科技学院 | 2023-12-19 | — | — | CN | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4167982-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | GAK 681/4885EPHB6 2967/4885RIPK2 2353/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | GAK 681/4885EPHB6 2967/4885RIPK2 2353/4885 |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | GAK 99/4885EPHB6 4512/4885RIPK2 1228/4885 |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | GAK 2180/4885EPHB6 4789/4885RIPK2 1319/4885 |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | GAK 2279/4885EPHB6 4007/4885RIPK2 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.